Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (201-210 of 260) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumorsDamien Faury, André Nantel, Sandra E Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy SpectrumLucia Nappi, Marisa Thi, Amy Lum, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2007
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor developmentMeritxell Gironella, Mylène Seux, Min-Jue Xie, et al.
Molecular Cancer Research : MCR|January 27, 2022
Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical ImplicationsXin Dong, Hui Xue, Fan Mo, et al.
The New England Journal of Medicine|October 22, 2025
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate CancerNeal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Cancer Letters|February 17, 2019
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cellsYongmei Feng, E Hampton Sessions, Fan Zhang, et al.
Nature Communications|April 14, 2018
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosisMargaux Sevin, Lucia Kubovcakova, Nicolas Pernet, et al.
The New England Journal of Medicine|October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerStephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Pageof 26

Showing results (201-210 of 260) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2007
Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumorsDamien Faury, André Nantel, Sandra E Dunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2019
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy SpectrumLucia Nappi, Marisa Thi, Amy Lum, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2007
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor developmentMeritxell Gironella, Mylène Seux, Min-Jue Xie, et al.
Molecular Cancer Research : MCR|January 27, 2022
Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical ImplicationsXin Dong, Hui Xue, Fan Mo, et al.
The New England Journal of Medicine|October 22, 2025
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate CancerNeal D Shore, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
Cancer Letters|February 17, 2019
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cellsYongmei Feng, E Hampton Sessions, Fan Zhang, et al.
Nature Communications|April 14, 2018
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosisMargaux Sevin, Lucia Kubovcakova, Nicolas Pernet, et al.
The New England Journal of Medicine|October 18, 2023
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate CancerStephen J Freedland, Murilo de Almeida Luz, Ugo De Giorgi, et al.
Pageof 26